MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.73
+0.15 (+0.39%)
At close: 4:00PM EDT

38.50 -0.23 (-0.59%)
After hours: 7:23PM EDT

Stock chart is not supported by your current browser
Previous Close38.58
Open38.05
Bid38.20 x 2200
Ask38.93 x 1800
Day's Range37.93 - 38.78
52 Week Range29.39 - 47.82
Volume2,512,290
Avg. Volume4,577,232
Market Cap19.964B
Beta1.32
PE Ratio (TTM)28.60
EPS (TTM)1.35
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est49.86
Trade prices are not sourced from all markets
  • Mylan, ServiceNow, FactSet & biotech
    CNBC Videos4 days ago

    Mylan, ServiceNow, FactSet & biotech

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • Mylan, Puma Technology, ServiceNow, Alphabet & the tech s...
    CNBC Videos5 days ago

    Mylan, Puma Technology, ServiceNow, Alphabet & the tech s...

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • General Electric, Microsoft and Mylan are the Yahoo Finance charts of the day.
    Yahoo Finance Video5 days ago

    General Electric, Microsoft and Mylan are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. General Electric (GE): Shares are down in early trade, at around .68%. GE was urged by France's finance minister to stick to its commitment to create 1,000 jobs at energy producer Alstom. The company made the commitment in 2015 when it bought Alstom's energy business, but GE subsequently said the target was out of reach. Microsoft (MSFT): Shares up here,  at .20%. Reuters is reporting that Microsoft is working on technology that would eliminate cashiers and checkout lines from stores. The technology would represent a challenge to Amazon's automated grocery stores. Mylan (MYL): Shares down here, at around 3.7%. U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.  For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Mylan CEO on FDA-approved biosimilar, Trump's drug price plan
    CBS News Videos7 days ago

    Mylan CEO on FDA-approved biosimilar, Trump's drug price plan

    Nearly two years after taking tremendous heat for the rising cost of EpiPens, pharmaceutical giant Mylan is making strides in the fast-growing biosimilar market. Biosimilars are drugs and devices made to be similar to already-approved products, potentially lowering the cost of treatment. Mylan won FDA approval last week for a biosimilar drug designed to help some cancer patients reduce infection risk during chemotherapy. Mylan CEO Heather Bresch joins "CBS This Morning" to explain how biosimilars could translate to patient savings, what the company learned from the EpiPen debacle, and why she applauds President Trump's plan to reduce drug costs.

  • Mylan Launches Generic Angiomax® Injection
    PR Newswireyesterday

    Mylan Launches Generic Angiomax® Injection

    HERTFORDSHIRE, England and PITTSBURGH, June 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Bivalirudin for Injection, 250 mg single-dose vial, a generic version of Angiomax® from The Medicines Company. The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.

  • Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
    Zacks4 days ago

    Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

    Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.

  • Company News For Jun 15, 2018
    Zacks4 days ago

    Company News For Jun 15, 2018

    Companies In The News are: ETSY,RCL,MYL,GSK,TWTR

  • Associated Press5 days ago

    FDA clears 1st generic film strip of addiction drug Suboxone

    U.S. regulators have approved the first generic version of an under-the-tongue film for treating opioid addiction.

  • Barrons.com5 days ago

    After the Bell: Dow Dips 26 Points, Nasdaq Hits New High as Market Tries to Make Up Its Mind

    The Dow Jones Industrial Average finished lower today, but the other major indexes fared better. •...and explain why Twitter (TWTR) soared. The S&P 500 has come to a standstill, but don't expect it to stay that way for long.

  • MarketWatch5 days ago

    FDA approves generic version of Suboxone film

    The U.S. Food and Drug Administration late Thursday said it approved the first generic version of a Suboxone under-the-tongue film for the treatment of opioid addiction. Mylan Technologies Inc., a subsidiary ...

  • Why Oracle, Mylan, and Tailored Brands Slumped Today
    Motley Fool5 days ago

    Why Oracle, Mylan, and Tailored Brands Slumped Today

    Find out why one of these stocks fell more than the others.

  • Mylan (MYL) to Get CRL Again for Generic Advair from FDA
    Zacks5 days ago

    Mylan (MYL) to Get CRL Again for Generic Advair from FDA

    Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

  • FDA Rejects Mylan’s Generic Advair Again, Stock Falls
    Market Realist5 days ago

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA didn’t approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination. The FDA cited “minor deficiencies” in Mylan’s ANDA (abbreviated new drug application) for its generic Advair, which was first dismissed by the FDA in March 2017.

  • Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven't
    Investor's Business Daily5 days ago

    Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven't

    Investors didn't cut Mylan any slack Thursday after the company announced U.S. regulators would likely delay its generic version of blockbuster asthma inhaler Advair.

  • General Electric dips, Microsoft up slightly, Mylan under pressure
    Yahoo Finance5 days ago

    General Electric dips, Microsoft up slightly, Mylan under pressure

    Let’s check out the Yahoo Finance charts of the day.

  • Tesla, Microsoft, Apple Rise in Pre-Market, Mylan Slumps
    Investing.com5 days ago

    Tesla, Microsoft, Apple Rise in Pre-Market, Mylan Slumps

    Investing.com - Stocks in focus in pre-market trade Thursday:

  • Reuters5 days ago

    US STOCKS-Wall St rises after ECB statement, retail sales data

    U.S. stocks rose on Thursday after the European Central Bank promised not to raise euro zone interest rates before the middle of next year and on better-than-expected May retail sales data. The bank's statement came as a relief, especially after the U.S. Federal Reserve raised interest rates for the second time this year on Wednesday and hinted at two more hikes by the end of 2018.

  • Stocks Start Higher On ECB Outlook: Etsy, 2 IPOs Seize New Highs
    Investor's Business Daily5 days ago

    Stocks Start Higher On ECB Outlook: Etsy, 2 IPOs Seize New Highs

    Mylan and Oracle dragged on early trade, but positive news out of Europe sent futures higher, and IPOs Etsy, Huya and Pivotal were poised to nail news highs.

  • Reuters5 days ago

    US STOCKS-Wall St set to open higher after ECB decision, retail sales data

    Wall Street was on track to open higher on Thursday after strong retail sales data, while investors assessed the European Central Bank's move to end its stimulus program and the Federal Reserve's guidance on monetary policy. The Fed raised its benchmark interest rates by 25 basis points for the second time this year on Wednesday and hinted at two more hikes by the end of 2018.

  • CNBC6 days ago

    After-hours buzz: TLRD, MYL & more

    Check out the companies making headlines after the bell on Wednesday: Shares of Tailored Brands TLRD plummeted nearly 20 percent after the bell, despite reporting first-quarter earnings and revenue that beat analysts' expectations.

  • TheStreet.com6 days ago

    Mylan Slumps in After-Hours Trading on Generic Advair Update

    Pounded. Mylan NV said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of GlaxoSmithKline plc's asthma drug Advair.

  • Reuters6 days ago

    FDA finds deficiencies in Mylan's generic Advair; shares fall

    Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment. Shares of Mylan fell 4.5 percent to $39.80 after the bell. Mylan did not provide details on the nature of the deficiencies cited by the U.S. Food And Drug Administration and it remains unclear whether the company will be able to resolve them and get approval this year.

  • Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler
    Investor's Business Daily6 days ago

    Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler

    Mylan shares plunged late Wednesday after the FDA identified "minor deficiencies" in its application for a generic copy of GlaxoSmithKline's drug Advair.

  • GlobeNewswire7 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Regency Centers, Motorola Solutions, California Resources, Echelon, Mylan N.V., and Nordstrom — New Research Emphasizes Economic Growth

    NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regency ...

  • Mylan CEO: Neulasta biosimilar will offer "significant savings" for patients
    CBS MoneyWatch8 days ago

    Mylan CEO: Neulasta biosimilar will offer "significant savings" for patients

    It's been nearly two years since the pharmaceutical giant took tremendous heat for the rising cost of EpiPens